NCT07384897 Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
| NCT ID | NCT07384897 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université Catholique de Louvain |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 425 participants |
| Start Date | 2025-02-17 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 425 participants in total. It began in 2025-02-17 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation. Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment. The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of lung cancer * Presence of precancerous lung lesions * Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment * Control group: individuals without known lung disease * Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD) * Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected Exclusion Criteria: * Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent) * Acute infection at the time of inclusion * Refusal or inability to provide informed consent (or assent, when applicable) * Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Contact & Investigator
Frank Aboubakar Nana, MD; PhD
STUDY DIRECTOR
Cliniques universistaires saint Luc
Frequently Asked Questions
Who can join the NCT07384897 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07384897 currently recruiting?
Yes, NCT07384897 is actively recruiting participants. Contact the research team at frank.aboubakar@saintluc.uclouvain.be for enrollment information.
Where is the NCT07384897 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT07384897 clinical trial?
NCT07384897 is sponsored by Université Catholique de Louvain. The principal investigator is Frank Aboubakar Nana, MD; PhD at Cliniques universistaires saint Luc. The trial plans to enroll 425 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.